Viridian Therapeutics Inc Stock Price, News & Analysis

Viridian Therapeutics has initiated a Phase 1 clinical trial for VRDN-002, a monoclonal antibody designed to treat thyroid eye disease (TED). This trial involves 16 healthy volunteers receiving ascending doses of VRDN-002 to assess its safety and efficacy as a low-volume subcutaneous injection. Results are anticipated mid-year. This milestone supports Viridian's strategy to enhance patient care for TED, potentially allowing for at-home self-administration or treatment in a physician's office.

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology firm focused on treating serious diseases, will have its CEO, Jonathan Violin, participate in a fireside chat at the 32nd Annual Oppenheimer Healthcare Conference on March 15, 2022, at 10:40 a.m. ET. This event highlights the company's efforts to advance new therapies, particularly VRDN-001, a monoclonal antibody for thyroid eye disease, and VRDN-002, a half-life extended treatment option. Interested parties can view the live webcast and replay on Viridian's website.

Viridian Therapeutics (NASDAQ: VRDN) reported financial results for Q4 and FY 2021, highlighting a strong cash position of $197 million to fund operations into 2024.

The company has two ongoing clinical trials for its IGF-1R antibodies, VRDN-001 and VRDN-002, targeting Thyroid Eye Disease (TED), with top-line data expected in Q2 and mid-2022, respectively.

Despite a net loss of $28.9 million in Q4 2021, this is an improvement from $90.7 million in the previous year, driven by reduced R&D expenses.

Viridian Therapeutics, Inc. (NASDAQ: VRDN) will report its financial results for the fourth quarter and full year ended December 31, 2021, on March 10, 2022, after market close. The management will host a conference call at 4:30 p.m. ET on the same day. Interested parties can listen by dialing 1-877-407-0789 (U.S.) or 1-201-689-8562 (international) with conference ID: 13727096. The call will also be available via live webcast on the company's investor site. Viridian focuses on developing treatments for serious diseases, targeting insulin-like growth factor-1 receptor for thyroid eye disease.

Viridian Therapeutics (NASDAQ: VRDN) announced that CEO Jonathan Violin, Ph.D., will participate in a Fireside Chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 18 at 2:20 PM ET. The event aims to discuss advancements in treatments for serious diseases, focusing on their lead product, VRDN-001, targeting thyroid eye disease (TED). This condition can cause severe complications, necessitating surgical interventions. A live webcast and replay of the chat will be available on Viridian's website.

Viridian Therapeutics has received FDA clearance for its investigational new drug application for VRDN-002, a novel monoclonal antibody using half-life extension technology. The VRDN-002 is designed for low-volume subcutaneous injection to treat thyroid eye disease (TED). The company plans to initiate a first-in-human Phase 1 clinical trial to assess safety and pharmacokinetics, with results expected in mid-2022. This marks a key developmental milestone as Viridian aims to enhance treatment convenience for TED patients.

Viridian Therapeutics has submitted an IND application to the FDA for VRDN-002, a monoclonal antibody designed for thyroid eye disease. This innovative therapy incorporates half-life extension technology, enabling low-volume subcutaneous administration. The company aims to initiate a Phase 1 clinical trial to assess the drug's safety, tolerability, and pharmacokinetics with results expected in mid-2022. CEO Jonathan Violin emphasized this step is critical for their clinical strategy, alongside upcoming data for VRDN-001.

Viridian Therapeutics has initiated a Phase 1/2 proof-of-concept clinical trial for VRDN-001, a monoclonal antibody targeting the IGF-1 receptor, aimed at treating thyroid eye disease (TED). The trial, which includes healthy volunteers and TED patients, evaluates safety, tolerability, and potential efficacy with top-line data expected in 2Q 2022. This trial follows preclinical data from over 100 oncology patients, suggesting promising safety and pharmacokinetics for VRDN-001, previously known as AVE1642.

Viridian Therapeutics (Nasdaq: VRDN) announced the approval of stock options for 180,000 shares to two new employees, granted as Inducement Grants. These grants, awarded outside of the company's 2016 Equity Incentive Plan, will vest over four years. The exercise price will match the stock's closing price on each employee's Grant Date. This move aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract talent to support Viridian's mission of developing treatments for serious diseases, including its leading program targeting thyroid eye disease.